Recently,
application of the flow technologies for the preparation
of fine chemicals, such as natural products or Active Pharmaceutical
Ingredients (APIs), has become very popular, especially in academia.
Although pharma industry still relies on multipurpose batch or semibatch
reactors, it is evident that interest is arising toward continuous
flow manufacturing of organic molecules, including highly functionalized
and chiral compounds. Continuous flow synthetic methodologies can
also be easily combined to other enabling technologies, such as microwave
irradiation, supported reagents or catalysts, photochemistry, inductive
heating, electrochemistry, new solvent systems, 3D printing, or microreactor
technology. This combination could allow the development of fully
automated process with an increased efficiency and, in many cases,
improved sustainability. It has been also demonstrated that a safer
manufacturing of organic intermediates and APIs could be obtained
under continuous flow conditions, where some synthetic steps that
were not permitted for safety reasons can be performed with minimum
risk. In this review we focused our attention only on very recent
advances in the continuous flow multistep synthesis of organic molecules
which found application as APIs, especially highlighting the contributions
described in the literature from 2013 to 2015, including very recent
examples not reported in any published review. Without claiming to
be complete, we will give a general overview of different approaches,
technologies, and synthetic strategies used so far, thus hoping to
contribute to minimize the gap between academic research and pharmaceutical
manufacturing. A general outlook about a quite young and relatively
unexplored field of research, like stereoselective organocatalysis
under flow conditions, will be also presented, and most significant
examples will be described; our purpose is to illustrate all of the
potentialities of continuous flow organocatalysis and offer a starting
point to develop new methodologies for the synthesis of chiral drugs.
Finally, some considerations on the perspectives and the possible,
expected developments in the field are briefly discussed.